Abstract: The present invention discloses a system and a methodology for enhancing performance during wireless communications by reducing system latency, MIPS requirements and power consumption. The present invention discloses a system and method of wireless data communication in which part of upper layer stack processing is performed on a controller to relieve a host processor of some data intensive operations. After the initial connection establishment phase in which the controller retrieves certain information required for data transmission and stores the same locally, the data source provides data directly to the controller without routing the data through the host. The host is relieved of the data processing that needs to be done while the data is being transferred. Hence, the overall latency of the system is improved because of the optimal routing of data traffic.

Abstract: This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, caboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, carboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

Abstract: A method is described that resets a first count and resets a second count if a first transmission unit is recognized as being within a new measurement time window. The first transmission unit has a size. The method also increments the first count by the first transmission unit size and by the size of each subsequent transmission unit that is received within the new measurement time window after the first transmission unit—so long as the first count does not exceed a maximum allowable value for the first count. The method also checks if a maximum value for the second count is exceeded if it is incremented by a second transmission unit size. The second transmission unit is received within the measurement time window. The check is in response to a determination that the first count would have exceeded the first count maximum allowable valuable if the first count were incremented by the second transmission unit size.

Abstract: Isoflavone compounds are described and recommended as therapeutic agents. Exemplified and preferred compounds are (a). Indications show compounds have good competitive binding to estrogen receptors. This is exemplified.

Abstract: A compound of the general formula (I) or (II) wherein X is O, NR4 or S and R1-R8 are as defined in the specification

Abstract: The invention describes antimicrobial silicone oligomers or polymers comprising a silicone oligomer or polymer associated with at least one compound of formula (I). Also described are methods of associating compounds of formula (I) to surfaces and products thereof.

Abstract: One embodiment of the present invention provides a system that facilitates accessing a credential. During operation, the system receives a request at a credentials-storage framework (CSF) to retrieve the credential. If a target credential store containing the credential is not already connected to the CSF, the system looks up a bootstrap credential for the target credential store in a bootstrap credential store, which contains bootstrap credentials for other credential stores. Next, the system uses this bootstrap credential to connect the CSF to the target credential store. Finally, the system retrieves the credential from the target credential store, and returns the credential to the requestor.

Abstract: The present invention provides a method for treating and/or preventing hepatic disease conditions in a subject mammals including human beings, said method comprising the steps of administering to the mammal an effective dosage of composition comprising 2?-p-Hydroxy benzoyl mussaenosidic acid from plant Vitex negundo optionally as individual or in combination with one or more pharmaceutically additives.

Abstract: Systems, methods, and machine-readable media are disclosed for providing conditional grants of permission in an externally configured security policy. In one embodiment, a method is provided which comprises reading a condition clause from a grant statement defined in the security policy. The grant statement can cause the granting of permission for a user to access a requested resource. One or more constraints on the grant statement can be determined based on the condition clause. Permission can be granted to access the requested resource based on the one or more constraints.

Abstract: Systems, methods, and machine-readable media are disclosed for providing dynamic and/or conditional constraints on queries based on an external security policy. In one embodiment, a method is provided which comprises receiving from a user a request to access a resource. A condition clause can be read from a grant statement defined in the security policy. The grant statement can define permission for the user to access the requested resource. In some cases, the grant statement can comprise a Java Authentication and Authorization Service (JAAS) grant statement. A query associated with the requested access can be modified based on the permission granted to the user. The modified query can then be made to perform the requested access.

Abstract: The invention relates to highly pure fexofenadine and a process for preparing highly pure fexofenadine. The invention also relates to pharmaceutical compositions that include the highly pure fexofenadine and use of said compositions for treating a patient for allergic reactions.

Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, caboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

Abstract: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0]hexanes, as well as pharmaceutical compositions containing such compounds and methods of treating diseases mediated through muscarinic receptors.

Abstract: This invention relates to derivatives of substituted azabicyclo hexanes. The compound of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

Abstract: A mass produced universal dental appliancee (1) comprises two parts, the parts intended in use to contact the posterior teeth on respective opposite sides of either the upper or lower jaw, each part comprising a composite structure comprising: i) a first layer (2) formed a durable, resilient, elastomeric material having a softening point in the range from 35 to 100° C. and which in use contacts and grips the occlusal biting surfaces of the posterior teeth; and ii) a second layer (3) formed from a durable, non-deformable material having a softening point over 100° C. and which in use provides a bite plate; wherein the second layer of each part is provided with a protrusion (5), formed of durable, non-deformable material having a softening point over 100° C.

Abstract: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of repaglinide.

Abstract: This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.